Speed, scale and discovery power with the NovaSeq X Series
Unlock deeper insights for more meaningful outcomes
Your email address is never shared with third parties.
With the NovaSeq X Series, you can take on projects that were previously out of reach. Sequence both broader and deeper at scale than ever before. The lower cost per Gb, higher-throughput, and fast, streamlined operational workflows allow you to sequence more samples and analyze data more easily than ever before.
The NovaSeq X Series and 1.5B, 10B, and 25B flow cells enable users to leverage budgets to perform sequencing studies of greater scale and depth.
* $200 USD genome on NovaSeq X Series is delivered at list price on the 25B flow cell (sequencing consumables only), assuming 100Gb/genome.
Increased discovery power will come from larger studies, deeper sequencing to identify rare genetic events, and broader sequencing methods and multiomics for a more comprehensive view of cellular activity. Learn how you can perform broader, deeper sequencing and take on projects that were previously out of reach with the NovaSeq X Series.
Your email address is never shared with third parties.
The NovaSeq X Series allows you to sequence more deeply to analyze rare variants, or scale up any application to include more samples. By leveraging the NovaSeq X Series 10B and 25B flow cells, you can work with bigger cohorts, faster than ever with the highest level of confidence.
Perform ctDNA sequencing to detect rare variants and low-frequency signals in liquid biopsy research samples.
Sequence historically challenging, medically relevant genes and better understand genetic disease with Illumina Complete Long Reads.
Access the contributions of individual cells in complex tissues by profiling up to millions of single cells in parallel, under more conditions, and at genome-scale.
Add statistical power and sequence 2.5× more samples by transitioning from the NovaSeq 6000 S4 flow cell to the NovaSeq X 25B flow cell.
Affordably analyze up to 64 human whole genomes per flow cell to power rare disease research.
Efficiently identify coding variants for larger cohort groups with the ability to sequence ~750 exomes per NovaSeq X 25B flow cell.
Exome sequencing was performed on the NovaSeq X Plus System with 25B flow cells and on the NovaSeq 6000 System with S4 flow cells using the same total project budget. This analysis is based on sequencing 8 Gb per exome.
The NovaSeq X Series allows you to sequence more deeply to analyze rare variants, or scale up any application to include more samples. By leveraging the NovaSeq X Series 10B and 25B flow cells, you can work with bigger cohorts, faster than ever with the highest level of confidence. Sequence 2.5x more cells in half the time* with the 25B flow cell on NovaSeq X Plus.
| NovaSeq X Flow Cell Type |  |
 |
 |
|---|---|---|---|
| No. of single-cells sequenced per run** | ~120,000 | ~800,000 | ~2M |
| Run time | ~17 hr*** | ~18 hr*** | ~48 hr*** |
* Compared to NovaSeq 6000 S4 200-cycle kit.
** Assumes 25,000 reads per cell.
*** Run time for 1.5B and 10B flow cells are based on 2 x 50 bp read configuration. Run time for 25B flow cell is based on 2 x 150 bp read configuration.
It's now easier to perform a broad range of multiomics studies and add an additional dimension of information with the NovaSeq X Series. Answer the most complex questions in genomics by getting the most information out of every single sample.
By combining multiple methods for deeper insights, you can think bigger with your projects and drive utility. Here are some of the top methods that are validated for the NovaSeq X Series and commonly combined for multiomics studies.
| Common multiomics combinations | Benefits | How NovaSeq X helps | Popular methods |
|---|---|---|---|
| Genomics + transcriptomics | Measure the functional consequences of genetic variation to annotate and prioritize variants associated with disease |
Automated, push-button onboard secondary analysis for WGS, WES, and RNA-Seq that can run in parallel |
|
| Genomics + epigenetics | Reveal patterns of gene regulation and how they connect with the genotypes underlying disease, especially in noncoding regions |
Automated onboard independent lane loading to easily sequence multiple omes on the same flow cell |
|
| Transcriptomics + epigenetics | Directly measure the ties between gene regulation and gene expression, instead of trying to infer those connections |
Seamlessly connected to full suite of DRAGEN secondary analysis pipelines in the cloud |
The NovaSeq X Series improves turnaround time and simplifies data analysis with DRAGEN onboard.
XLEAP-SBS chemistry delivers exceptional data quality for high-throughput genomics, and technology advances make the NovaSeq X Series our most powerful and cost-effective sequencing systems yet.
Implementing sequencing workflows is faster and easier than ever before with the NovaSeq X Series. There are fewer touch points and steps, from run planning to sequencing and analysis. Accelerate your sequencing with the streamlined workflow and easily manage large amounts of data with DRAGEN onboard the NovaSeq X Series.
Illumina Run Manager
*Connected Insights available in select countries
There is nothing more important than innovation at Illumina. It’s how we move the field forward and it’s part of everything we do. See how every detail has been redesigned in the NovaSeq X Series to elevate usability, maximize productivity, and minimize turnaround to make the most of your precious samples.
Feeding the world’s growing population requires big advances in sustainable aquaculture, and in this video, three scientists describe how the Illumina NovaSeq X Series is helping make those advances possible.
The Ontario Institute for Cancer Research is working to better understand tumor biology and improve cancer care through the use of genomics. Learn how OICR is using the NovaSeq™ X Plus to accelerate projects, like those with Dr. Stephanie Lheureux at Princess Margaret.
Talk to an expert about adopting broader and deeper sequencing approaches in your lab.
Your email address is never shared with third parties.